Neurocrine Biosciences In... (NBIX)

If you work in the biotech industry, you might know the name Alex Denner.

Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NBIX -3.11%) hasn't been wowing analysts lately. On Monday, no less than thr...

On Thursday, Neurocrine Biosciences Inc. NBIX reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56.

Neurological therapeutics specialist Neurocrine Biosciences (NBIX -0.46%) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnin...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Execu...

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.44 per share a year ago.

Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr...

Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment for CA...

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.